Inclusion Criteria:

1. Male ≥18 years of age at the time of signing informed consent
2. Histologically or cytologically confirmed adenocarcinoma of the prostate
3. Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible
4. Adequate organ function

Exclusion Criteria:

1. Prior solid organ transplant
2. Prior treatment with PSMA-targeted CAR-T cell therapy
3. Clinically significant cardiovascular disease
4. Active clinically significant infection (bacterial, viral, fungal, mycobacteria or other)
5. Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment